Brief: Immix Biopharma Accelerates Enrollment In U.S. AL Amyloidosis Trial Of NXC-201 CAR-T
Jan 7 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA ACCELERATES ENROLLMENT IN U.S. AL
AMYLOIDOSIS
TRIAL OF NXC-201 CAR-T
* IMMIX BIOPHARMA INC: ON TRACK FOR NEXT PROGRAM UPDATE IN
Q1 2025
Source text: ID:nGNX1WJxc4
Further company coverage: IMMX.O
(((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary